stockportfolio.pro
MiMedx Group, Inc. (MDXG)
Healthcare · Biotechnology · NasdaqCM
MiMedx Group, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $221.71M | $321.14M | $359.11M | $299.25M | $248.23M | $242.02M | $267.84M | $321.48M | $348.88M | $418.63M |
| Gross profit | $190.77M | $285.92M | $322.73M | $256.17M | $208.90M | $202.39M | $219.53M | $266.84M | $288.81M | $345.62M |
| Net income | $390,000 | $64.73M | $-29.98M | $-25.58M | $-49.28M | $-10.29M | $-30.20M | $58.23M | $42.42M | $48.58M |
| Net margin | 0.2% | 20.2% | -8.3% | -8.5% | -19.9% | -4.2% | -11.3% | 18.1% | 12.2% | 11.6% |
Source: MiMedx Group, Inc. SEC filings (10-K). 16 years of history available in the interactive view.
What growth is priced into MDXG stock?
At today's market cap of $536.95M, MiMedx Group, Inc. is priced for free-cash-flow growth of about -6.3% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $72.97M from the FY ending 2025-12-31). For comparison, revenue 11%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 16 years of MiMedx Group, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track MDXG in your portfolio →
MiMedx Group, Inc. financial history by metric
About MiMedx Group, Inc.
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.
MiMedx Group, Inc. — frequently asked questions
What is MiMedx Group, Inc.'s revenue?
MiMedx Group, Inc. (MDXG) reported revenue of $418.63M for fiscal year 2025, up 20.0% from the prior year, according to its SEC filings.
Is MiMedx Group, Inc. profitable?
Yes. MDXG earned net income of $48.58M in fiscal 2025, a net margin of 11.6%.
What is MDXG's P/E ratio?
MiMedx Group, Inc. trades at a price-to-earnings ratio of about 18.0 based on the latest data in our nightly-refreshed cache.
How fast is MiMedx Group, Inc. growing?
MDXG's revenue grew at roughly 11.0% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does MiMedx Group, Inc. have?
As of fiscal year 2025, MDXG carried roughly $17.97M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is MiMedx Group, Inc.'s gross margin?
MDXG's gross margin was 82.6% in fiscal 2025 — gross profit of $345.62M on revenue of $418.63M.
What is MiMedx Group, Inc.'s market cap?
MiMedx Group, Inc. (MDXG) has a market capitalization of about $536.95M, based on the latest data in our nightly-refreshed cache.
When does MiMedx Group, Inc.'s fiscal year end?
MDXG's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into MDXG stock?
At today's market cap of $536.95M, MiMedx Group, Inc. is priced for free-cash-flow growth of about -6.3% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $72.97M from the FY ending 2025-12-31). For comparison, revenue 11%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from MiMedx Group, Inc.'s official SEC filings (10-K and 10-Q), covering 16 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.